A new clinical trial underway at the Royal National Orthopaedic Hospital in Stanmore, in the London Borough of Harrow, is exploring a promising intervention that could significantly improve outcomes for individuals living with spinal cord injuries (SCI). The study, titled ‘ImPRESS’, is investigating the use of epidural nerve stimulation to restore bladder and bowel function, two of the most persistent and costly complications associated with SCI.

The first three participants have now received the implantable nerve stimulation device, marking a key milestone in the trial. The device delivers targeted electrical pulses to specific nerves at the junction with the spinal cord, and is used in conjunction with pelvic muscle training in a home-based setting. This dual approach aims to improve continence and reduce the incidence of infections and other complications that often require ongoing medical intervention.

From an insurance perspective, the implications of this research are substantial. Bladder and bowel dysfunctions are not only detrimental to quality of life but also contribute significantly to long-term care costs. Frequent hospital admissions, catheter-related infections, and the need for personal care support are common among SCI patients. If successful, the ImPRESS trial could reduce reliance on these services, potentially lowering claims related to chronic care, rehabilitation, and secondary complications.

The trial is expected to conclude in 2027, with researchers hopeful that the findings will support broader adoption of nerve stimulation as a standard therapeutic option. For insurers, this could represent a shift in how SCI-related claims are managed, moving from reactive treatment models to proactive, restorative care strategies.

Moreover, improved bladder and bowel control can enhance independence and mental wellbeing, which may positively influence return-to-work outcomes and reduce the need for long-term disability support. This aligns with broader industry goals of promoting recovery, reducing risk exposure, and supporting sustainable rehabilitation pathways.

While still in its early stages, the ImPRESS trial reflects the growing role of technology in reshaping the future of healthcare. For insurers, staying informed about such innovations is key to anticipating changes in care delivery, policy design, and claims management.